Fumihiko Ushigome
Overview
Explore the profile of Fumihiko Ushigome including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Otsuka Y, Poondru S, Bonate P, Rose R, Jamei M, Ushigome F, et al.
J Pharmacokinet Pharmacodyn
. 2023 Jun;
50(5):365-376.
PMID: 37344637
Enzalutamide is known to strongly induce cytochrome P450 3A4 (CYP3A4). Furthermore, enzalutamide showed induction and inhibition of P-glycoprotein (P-gp) in in vitro studies. A clinical drug-drug interaction (DDI) study between...
2.
Shimamura M, Miyakawa J, Doi M, Okada K, Kurumatani H, Mori Y, et al.
J Clin Pharmacol
. 2016 Sep;
57(4):524-535.
PMID: 27681484
The purpose of the present study was to evaluate the pharmacokinetics of beraprost sodium (BPS) and its active enantiomer, BPS-314d, in Japanese subjects with impaired kidney function. The plasma and...
3.
Zhang W, Krauwinkel W, Keirns J, Townsend R, Lasseter K, Plumb L, et al.
Clin Drug Investig
. 2013 Jun;
33(7):489-96.
PMID: 23733389
Background: Ipragliflozin (ASP1941), a potent selective sodium glucose co-transporter 2 inhibitor, is in development for the treatment of type 2 diabetes mellitus. Ipragliflozin is primarily eliminated via conjugation by the...
4.
Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, et al.
Mol Pharm
. 2013 Apr;
10(5):1783-94.
PMID: 23560393
Mirabegron, a weak-basic compound, is a potent and selective β3-adrenoceptor agonist for the treatment of overactive bladder. Mirabegron extended release formulation shows dose-dependent oral bioavailability in humans, which is likely...
5.
Yamashita F, Ohtani H, Koyabu N, Ushigome F, Satoh H, Murakami H, et al.
J Pharm Pharmacol
. 2006 Nov;
58(11):1499-505.
PMID: 17132213
Human organic anion transporter 4 (OAT4) is the only member of the OAT family that is expressed in the placenta and also expressed in kidney. Although OAT4 has been shown...
6.
Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, et al.
Br J Pharmacol
. 2004 Oct;
143(7):856-64.
PMID: 15504753
We investigated the effects of grapefruit juice (GFJ) and orange juice (OJ) on drug transport by MDR1 P-glycoprotein (P-gp) and multidrug resistance protein 2 (MRP2), which are efflux transporters expressed...
7.
Ushigome F, Koyabu N, Satoh S, Tsukimori K, Nakano H, Nakamura T, et al.
Pharm Res
. 2003 Mar;
20(1):38-44.
PMID: 12608534
Purpose: P-Glycoprotein (Pgp) plays an important role in drug disposition and excretion in various tissues such as the brain, intestine, and kidney. Moreover, we have demonstrated that Pgp is expressed...
8.
Inuyama M, Ushigome F, Emoto A, Koyabu N, Satoh S, Tsukimori K, et al.
Am J Physiol Cell Physiol
. 2002 Aug;
283(3):C822-30.
PMID: 12176739
The characteristics of L-lactic acid transport across the trophoblast basal membrane were investigated and compared with those across the brush-border membrane by using membrane vesicles isolated from human placenta. The...
9.
Emoto A, Ushigome F, Koyabu N, Kajiya H, Okabe K, Satoh S, et al.
Am J Physiol Cell Physiol
. 2002 Apr;
282(5):C1064-75.
PMID: 11940522
We investigated the transport of salicylic acid and L-lactic acid across the placenta using the human trophoblast cell line BeWo. We performed uptake experiments and measured the change in intracellular...
10.
Nakamura H, Ushigome F, Koyabu N, Satoh S, Tsukimori K, Nakano H, et al.
Pharm Res
. 2002 Mar;
19(2):154-61.
PMID: 11883642
Purpose: To investigate the transport mechanism of valproic acid across the human placenta, we used human placental brush-border membrane vesicles and compared them with that of lactic acid. Methods: Transport...